Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
1	17/SC/0345	225047	A Phase 1b, Open-label, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of MK-7655A in Pediatric Subjects From Birth to Less Than 18 Years of Age With Confirmed or Suspected Gram-negative Infections	Range Agreed	3	6	Date Agreed	31/10/2020	1	1	01/07/2020	Recruitment finished	Study closed internationally before we were able to recruit more participants
2	17/EM/0412	234907	An adaptive seamless randomized, double-blind, placebo-controlled, dose ranging study to investigate the efficacy and safety of LNP023 in primary IgA nephropathy patients	Number Agreed	3	3	Date Agreed	01/03/2024	2	2	01/07/2020	Recruitment finished	
3	18/SW/0049	237051	A Multicenter, Open-Label, Phase 1B/2 Study to Evaluate Safety and Efficacy of Avelumab (MSB0010718C) in Combination with Chemotherapy with or without Other Anti-Cancer Immunotherapies as First-Line Treatment in Patients with Advanced Malignancies	Range Agreed	1	3	Date Agreed	21/08/2020	4	4	12/08/2020	Recruitment finished	
4	18/EM/0005	236933	An Observational Study of Blinatumomab Safety and Effectiveness, Utilisation, and Treatment Practices	Range Agreed	2	4	Date Agreed	30/09/2020	5	5	10/08/2020	Recruitment finished	
5	18/NE/0235	244048	A Phase IIb Randomized, Double-blind, Parallel Group, Placebo- and Active-controlled Study with Double-Blind Extension to Assess the Efficacy and Safety of Vamorolone in Ambulant Boys with Duchenne Muscular Dystrophy (DMD)	Range Agreed	7	10	Date Agreed	30/09/2020	5	5	31/08/2020	Recruitment finished	
6	18/NE/0360	254062	An open-label, non-randomised study on efficacy, pharmacokinetics, pharmacodynamics, safety and tolerability of LNP023 in two patient populations with C3 glomerulopathy	Range Agreed	2	4	Date Agreed	31/07/2021	5	5	21/08/2020	Recruitment finished	
7	18/SC/0392	244109	Phase 2 Multicenter, Double-Blind, Placebo-Controlled, Efficacy, Safety, and Pharmacokinetic Study of 2 Doses of CXA-10 on Stable Background Therapy in Subjects with Pulmonary Arterial Hypertension (PAH)	Range Agreed	1	20	Date Agreed	31/12/2020	0	0	02/07/2020	Withdrawn by sponsor	Complexa decided to terminate the study CXA-10-301 (PRIMEx) due to delays in recruitment of PRIMEx patients, creating a minimum 6 month delay due to COVID-19
8	18/LO/1859	252363	Observational cohort study of patients with hormone receptor-positive metastatic breast cancer treated with palbociclib (Ibrance®) as part of the United Kingdom Ibrance® Patient Program (IPP); the Real Outcomes Ibrance® Study (ROIS)	Number Agreed	50	50	Date Agreed	31/12/2020	10	10	03/08/2020	Recruitment finished	
9	19/NE/0076	242027	BIOTRONIKS - Safety and Performance in de Novo Lesion of Native Coronary Arteries with Magmaris- Registry: BIOSOLVE-IV	Number Agreed	4	4	Date Agreed	06/10/2020	9	9	14/07/2020	Recruitment finished	
10	18/LO/1397	247266	A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients with Diabetic Gastroparesis	Number Agreed	2	2	Date Agreed	02/10/2020	0	0	04/09/2020	Withdrawn by sponsor	The sponsor took a decision to terminate the program

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
11	19/SC/0256	263749	A 12-month prospective, randomized, interventional, global, multi-center, active-controlled study comparing sustained benefit of two treatment paradigms (erenumab qm vs. oral prophylactics) in adult episodic migraine patients	Number Agreed	2	2	Date Agreed	12/04/2022	0	0	25/08/2020	Withdrawn by sponsor	In the UK we were slower to reactivate sites after the lockdown and other centers abroad recruited faster
12	19/NW/0504	264255	Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of BHV-3241 in Subjects with Multiple System Atrophy	Range Agreed	5	20	Date Agreed	31/10/2020	5	5	22/07/2020	Recruitment finished	
13	16/EM/0240	203358	A Randomized, Open-label, Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Patients With Relapsed or Refractory Mature B-cell non-Hodgkin Lymphoma	Range Agreed	1	3	Date Agreed	25/11/2020	0	0	05/08/2020	Withdrawn by sponsor	The study closed nationally as interim analysis showed futility of the trial therapy
14	16/WM/0437	206885	A Phase 3 Multicenter, Open-label, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Number Agreed	5	5	Date Agreed	18/12/2020	2	2	21/08/2020	Recruitment finished	
15	17/NW/0247	222303	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Cenicriviroc in Adult Subjects with Nonalcoholic Steatohepatitis and Liver Fibrosis	Range Agreed	200	300	Date Agreed	31/12/2022	1	1	12/08/2020	Withdrawn by sponsor	The sponsor took the decision to close the AURORA study and discontinue its NASH cenicriviroc [CVC] research & development program following the completion and analysis of the Part 1 section of the AURORA Phase III study.
16	17/WM/0460	237521	PROJECT TITLE: Cabozantinib PASS Study- F-FR-60000-001 Prospective non-interventional study of cabozantinib tablets in adults with advanced renal cell carcinoma following prior vascular endothelial growth factor (VEGF)-targeted therapy.	Range Agreed	50	113	Date Agreed	30/08/2021	7	7	30/09/2020	Recruitment finished	
17	18/ES/0029	239530	A subject-, investigator-, and sponsor-blinded, randomized, placebo-controlled, multicenter study to investigate efficacy, safety, and tolerability of VAY736 in patients with idiopathic pulmonary fibrosis	Range Agreed	3	6	Date Agreed	10/02/2021	1	1	31/12/2020	Withdrawn by sponsor	The sponsor closed to recruitment earlier than planned in December following the interim analysis
18	17/NE/0331	229957	A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair using the Fenestrated Anaconda™ device	Number Agreed	1	1	Date Agreed	30/06/2025	6	6	31/12/2020	Recruitment finished	
19	18/LO/0552	242687	Comprehensive Outcomes Registry in Subjects with Epilepsy Treated with Vagus Nerve Stimulation Therapy®	Range Agreed	2	4	Date Agreed	30/01/2021	14	14	31/12/2020	Withdrawn by sponsor	Sponsor closed the study early (from company end) due to commercial realignment of strategy.
20	18/NE/0292	252024	A Phase III Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Idebenone in Patients with Duchenne Muscular Dystrophy (DMD) who completed the SIDEROS study	Number Agreed	4	4	Date Agreed	31/03/2021	4	4	06/10/2020	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
21	19/LO/0153	259690	A randomized, double-blind, placebo-controlled, phase II, cross-over clinical trial evaluating the efficacy and safety of KVD900, an oral plasma kallikrein inhibitor, in the on-demand treatment of angioedema attacks in adult subjects with hereditary angioedema type I or II	Range Agreed	1	5	Date Agreed	10/08/2021	2	2	02/10/2020	Recruitment finished	
22	18/EM/0193	243749	A RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PARALLEL, ACTIVE-CONTROL STUDY OF THE EFFECTS OF SPARSENTAN, A DUAL ENDOTHELIN RECEPTOR AND ANGIOTENSIN RECEPTOR BLOCKER, ON RENAL OUTCOMES IN PATIENTS WITH PRIMARY FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)	Number Agreed	1	1	Date Agreed	31/10/2022	1	1	31/12/2020	Recruitment finished	Recruitment finished early nationally
23	19/LO/1500	269558	Basic Evaluation Lead Post-Market Clinical Follow-up (BASIC) Study	Number Agreed	2	2	Date Agreed	15/06/2021	6	6	02/10/2020	Recruitment finished	
24	20/HRA/2191	283184	Recombinant InterLeukin-7 (CYT107) to Improve clinical outcomes in lymphopenic pAtients with COVID-19 infection “ILIAD 7 trial”	Range Agreed	1	2	Date Agreed	11/01/2021	3	3	25/11/2020	Recruitment finished	
25	20/YH/0174	283089	A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.	Number Agreed	1	1	Date Agreed	27/08/2021	2	2	13/12/2020	Recruitment finished	Recruitment ended early nationally
26	12/YH/0313	106560	A European multi-centre, multi-country, post-authorisation, observational study (registry) of patients with chronic adrenal insufficiency	Range Agreed	15	20	Date Agreed	31/01/2021	271	271	31/10/2020	Recruitment finished	
27	19/WM/0056	256301	Multi-center cross-sectional epidemiological study to characterize the prevalence and distribution of lipoprotein(a) levels among patients with established cardiovascular disease	Range Agreed	2	7	Date Agreed	31/10/2020	112	112	27/02/2021	Recruitment finished	
28	19/SC/0034	254823	A Phase 3, randomized, double-blind, parallel-group, placebo controlled multicenter study to evaluate the efficacy and safety of two doses of GLPG1690 in addition to local standard of care for minimum 52 weeks in subjects with idiopathic pulmonary fibrosis.	Range Agreed	2	4	Date Agreed	31/03/2021	2	2	10/02/2021	Withdrawn by sponsor	Recruitment ended early nationally
29	18/SW/0199	249896	Screening Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)	Number Agreed	35	35	Date Agreed	15/01/2021	1	1	26/02/2021	Recruitment finished	
30	19/EM/0072	256161	A Long-Term, Randomized, Double-Blind, Multicenter, Parallel-group, Phase III Study Evaluating the Efficacy and Safety of PT027 Compared to PT007 Administered as needed in Response to Symptoms in Symptomatic Adults and Children 4 years of Age or Older with Asthma (MANDALA)	Number Agreed	9	9	Date Agreed	28/02/2021	3	3	30/01/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
31	19/LO/0357	258769	A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 as Adjunctive Therapy in Focal-onset Epilepsy.	Number Agreed	4	4	Date Agreed	30/11/2020	0	0	26/03/2021	Withdrawn by PI	Chronic understaffing due to COVID meant the team were unable to find recruits for the study. The PI took the decision that it wasn't currently safe to continue with the study
32	19/NW/0716	273613	A Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects	Range Agreed	40	50	Date Agreed	30/06/2021	5	5	08/02/2021	Recruitment finished	
33	20/YH/0090	278137	AN OPEN-LABEL,MULTICENTER, ROLLOVER STUDYTO EVALUATE THE SAFETY AND TOLERABILITY OF LONG-TERM ADMINISTRATION OFGANTENERUMABIN PARTICIPANTSWITHALZHEIMER'S DISEASE	Number Agreed	5	5	Date Agreed	07/06/2021	1	1	31/03/2021	Recruitment finished	
34	20/YH/0231	284781	A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA	Number Agreed	4	4	Date Agreed	16/07/2021	2	2	28/02/2021	Recruitment finished	
35	20/HRA/4325	288451	A retrospective study of the characteristics and outcomes of patients with familial chylomicronaemia syndrome treated with volanesorsen in the United Kingdom early access to medicines scheme	Range Agreed	5	10	Date Agreed	30/06/2021	1	1	11/01/2021	Recruitment finished	
36	20/EM/0142	282923	Phase IIb Multi-Center, Randomised, Partial-Blind Parallel Cohort Study to Assess the Efficacy and Safety of Treatment with GSK3228836 in Participants with Chronic Hepatitis B Virus (B-Clear)	Number Agreed	3	3	Date Agreed	05/03/2021	1	1	31/03/2021	Recruitment finished	
37	20/LO/0461	279984	Real-World Anti-VEGF Treatment Experience Study of the Management of Neovascular Age-Related Macular Degeneration in the UK (RATE Study in nAMD)	Range Agreed	2	6	Date Agreed	28/04/2021	17	17	31/01/2021	Recruitment finished	
38	16/LO/1637	211258	First-in-human, open-label, dose-escalation trial with expansion cohorts to evaluate safety of Axl-specific antibody-drug conjugate (HuMax®-AXL-ADC) in patients with solid tumors	Range Agreed	2	5	Date Agreed	31/03/2021	12	12	31/10/2020	Recruitment finished	
39	19/YH/0301	268446	A Phase 2 Study of ABBV-3067 Alone and in Combination with ABBV-2222 in Cystic Fibrosis Subjects Who Are Homozygous for the F508del Mutation	Range Agreed	1	3	Date Agreed	30/06/2021	0	0	22/03/2021	Withdrawn by sponsor	M19-530 study is now closed in the UK and Ethics has been notified of Permanent closure. Abbvie will now begin close out activities for all sites that had a finalised contract in place.
40	20/HRA/5205	289098	A PHASE I/II RANDOMIZED, TWO PARTS, DOSE-FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND IMMUNOGENICITY OF AN INACTIVATED, ADJUVANTED SARS-COV-2 VIRUS VACCINE CANDIDATE (VLA2001), AGAINST COVID-19 IN HEALTHY INDIVIDUALS	Range Agreed	1	10	Date Agreed	07/04/2021	37	37	15/01/2021	Recruitment finished	

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
41	19/LO/1986	273932	AMD Barometer - Investigating patient-driven barriers to long-term anti-VEGF treatment adherence in wet AMD.	Range Agreed	1	2	Date Agreed	30/04/2021	9	9	28/02/2021	Recruitment finished	
42	18/SC/0286	246516	A Randomised, Double-blind, Parallel-group, Placebo-controlled, Phase Ia/Ib, Multiple-site Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of KL1333 after a Single Oral Dose and Multiple Ascending Oral Doses in Healthy Subjects and Patients with Primary Mitochondrial Disease	Range Agreed	1	10	Date Agreed	30/06/2021	4	4	30/11/2020	Recruitment finished	
43	18/LO/1923	253458	A descriptive non-interventional study to evaluate the use of direct oral anticoagulants in UK clinical practice for patients with a first stroke attributable to nonvalvular atrial fibrillation	Number Agreed	200	200	Date Agreed	09/04/2021	43	43	30/06/2021	Recruitment finished	
44	19/NE/0260	265062	An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy	Range Agreed	120	200	Date Agreed	03/06/2021	5	5	30/04/2021	Recruitment finished	
45	19/EM/0111	262811	CRTH258C2302: An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion (RAVEN)	Number Agreed	1	1	Date Agreed	31/05/2021	4	4	27/05/2021	Recruitment finished	
46	19/NE/0247	259906	A Phase 2, Double-blind, Active-controlled, Dose-titrating Efficacy and Safety Study of Firibastat (QGC001) Compared to Ramipril Administered Orally, Twice Daily, Over 12 Weeks to Prevent Left Ventricular Dysfunction after Acute Myocardial Infarction	Range Agreed	5	10	Date Agreed	30/06/2021	4	4	30/06/2021	Recruitment finished	Study recruitment was impacted by COVID-19 and the study team was unable to meet the target of 5
47	19/NE/0269	268944	A Phase 3 Randomized, Open-Label, Study of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for First-line Treatment of Advanced or Recurrent Endometrial Carcinoma (LEAP-001)	Number Agreed	3	3	Date Agreed	05/03/2021	3	3	19/02/2021	Recruitment finished	
48	19/SC/0209	263492	A multinational, multicentre, prospective non-interventional study to assess safety and effectiveness of opicapone plus standard of care in elderly patients with Parkinson's Disease	Range Agreed	2	6	Date Agreed	28/04/2021	2	2	22/04/2021	Recruitment finished	
49	20/NE/0032	273692	A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ATEZOLIZUMAB PLUS CARBOPLATIN AND ETOPOSIDE WITH OR WITHOUT TIRAGOLUMAB (ANTI-TIGIT ANTIBODY) IN PATIENTS WITH UNTREATED EXTENSIVE-STAGE SMALL CELL LUNG CANCER	Range Agreed	2	5	Date Agreed	31/03/2021	0	0	11/03/2021	Recruitment finished	The team failed to recruit any patients. Due to coronavirus the patients were presenting with more advanced disease and poorer performance status than would be eligible for the study

Number	Research Ethics Committee Reference Number	Intergrated Research Application System (IRAS) Number	Name of Trial	Target number of patients Agreed	Minimum number of patients agreed to be recruited	Maximum number of patients agreed to be recruited	Whether or not a target date to rectruit patients was agreed	Date Agreed to recruit target number of patients	Total number of patients recruited at the agreed target date	Total number of study participants recruited	Date that the trial closed to recruitment	Reason for the closure of the trial	Comments
50	20/SC/0031	275229	A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Subjects with Moderate-to-Severe Atopic Dermatitis	Range Agreed	1	3	Date Agreed	30/06/2021	0	0	22/04/2021	Withdrawn by sponsor	Global recruitment ended prior to staff capacity issues being resolved at local site
51	20/NW/0383	287807	A Phase 3 Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of COVID-19 in an Outpatient Setting	Range Agreed	1	10	Date Agreed	07/04/2021	0	0	07/04/2021	Withdrawn by sponsor	After careful consideration, Gilead (Sponsor) made the decision to stop enrollment in study GS-US-540-9012. In light of recent advances, the primary unmet need for patients outside of the hospital setting is for convenient, effective therapies that can be easily administered at home.
52	20/NW/0177	1003027	Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects with Alzheimer's disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205.	Range Agreed	1	2	Date Agreed	30/04/2021	1	1	30/04/2021	Recruitment finished	
53	20/WA/0203	281292	POLARx Cardiac Cryoablation system Post Market Clinical Follow-up study	Range Agreed	1	10	Date Agreed	30/06/2021	10	10	26/05/2021	Recruitment finished	
54	20/YH/0317	288552	A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older	Number Agreed	200	200	Date Agreed	09/04/2021	207	207	09/04/2021	Recruitment finished	
55	21/NW/0125	294164	A RANDOMIZED, OBSERVER-BLIND, CONTROLLED, SUPERIORITY STUDY TO COMPARE THE IMMUNOGENICITY AGAINST COVID-19, OF VLA2001 VACCINE TO AZD1222 VACCINE, IN ADULTS	Range Agreed	120	200	Date Agreed	03/06/2021	134	134	03/06/2021	Recruitment finished	
56	19/LO/1753	269460	A phase 2, randomised, double-blind, placebo controlled study to evaluate the safety, efficacy, pharmacodynamics, and pharmacokinetics of SAR339375 for subutaneous injection administered every week in patients with Alport Syndrome	Number Agreed	1	1	Date Agreed	31/05/2021	2	2	31/05/2021	Recruitment finished	